LRP、TOPOⅡ及GSTπ-在非小细胞肺癌中的表达及临床意义

Expression and clinical significance of lung resistance protein,topoisomeraseⅡ and glutathione-S-transferase-π in non-small cell lung cancer

目的探讨肺耐药蛋白(lung resistance protein,LRP),DNA拓扑异构酶Ⅱ(topoisomeraseⅡ,TOPOⅡ),谷胱甘肽-S-转移酶-π(glutathione-S-transferase-π,GST-π)在非小细胞肺癌(non-small cell lung cancer,NSCLC)的表达及其临床意义。方法采用免疫组化技术(S-P法)检测57例术前均未进行化疗的非小细胞肺癌中LRP、TOPOⅡ及GST-π的表达情况。结果在NSCLC中LRP、TOPOⅡ及GST-π的表达阳性率分别为68.42%(39/57),66.67%(38/57)和84.21%(48/57),三者的表达均与病人的年龄、性别、肿瘤的大体类型、淋巴结转移以及临床分期无关(P>0.05),而与肿瘤的分化程度相关,高中分化与低分化之间差异有显著性(P<0.05)。且TOPOⅡ表达与组织学类型相关,鳞癌组的表达显著高于腺癌和细支气管肺泡癌(P<0.05)。结论LRP、GST-π和TOPOⅡ共同参与了NSCLC的固有耐药,表达的差异提示对药物敏感度不同,联合检测为制定科学有效的治疗方案具有临床意义。

Objective To investigate the expression and evaluate clinical significances of lung resistance protein （ LRP）, topoi- somerase H （TOPO Ⅱ） , glutathione-S-transferase-π（ GST-π） in non-small cell lung cancer （ NSCLC）. Methods Immunohistochemical S-P method was used to examine the expression of LRP, TOPO Ⅱ and GST-π in 57 NSCLC cases. Results The positive rates of LRP, TOPO Ⅱ and GST-π in NSCLC were 68.42% （39/57.） ,66. 67% （38/57） and 84. 21% （48/57） ,which were not correlated with age, sex, position, lymph node metastasis and TNM stage （P 〉 0. 05 ）. The positive rates were correlated with the degree of tumor differentiation, the poorly differentiated carcinomas were significantly different with well - differentiated and moderately differentiated carcinomas （ P 〈 0. 05 ）. And the expression of TOPO Ⅱ was correlated with histological types, the positive rate in squamous-cell carcinoma was higher than that in adenocarcinoma and bronchioalveolar carcinoma （ P 〈 0. 05 ）. Conclusion LRP, TOPO Ⅱ and GST-πintervene in the original muhi-drug resistance together. The expression difference indicates the sensitive difference to pharmaceuticals of NSCLC. The expression status detection of LRP, TOPO H and GST-π is significant for making scientific and efficient clinical treatment plan.